Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia.

Merchant S, Gast C, Nathwani D, Lee M, Quintana A, Ketter N, Friedland I, Ingham M.

Clin Ther. 2008 Apr;30(4):717-33.

PMID:
18498921
2.

Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.

Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I.

Crit Care Med. 2008 Apr;36(4):1089-96. doi: 10.1097/CCM.0b013e3181691b99.

PMID:
18379232
3.

Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia.

McGarry LJ, Merchant S, Nathwani D, Pawar V, DeLong K, Thompson D, Akhras K, Ingham M, Weinstein MC.

J Med Econ. 2010 Mar;13(1):142-7. doi: 10.3111/13696991003604108.

PMID:
20136579
4.

Clinical and economic consequences of ventilator-associated pneumonia.

Amin A.

Clin Infect Dis. 2009 Aug 15;49 Suppl 1:S36-43. doi: 10.1086/599814.

PMID:
19619020
5.

Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.

Kollef MH, Nathwani D, Merchant S, Gast C, Quintana A, Ketter N.

Crit Care. 2010;14(3):R84. doi: 10.1186/cc9012. Epub 2010 May 10.

6.

Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.

Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I.

Clin Ther. 2008 May;30(5):868-83. doi: 10.1016/j.clinthera.2008.04.019.

PMID:
18555934
7.

Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation.

Kongnakorn T, Mwamburi M, Merchant S, Akhras K, Caro JJ, Nathwani D.

Curr Med Res Opin. 2010 Jan;26(1):17-24. doi: 10.1185/03007990903358980.

PMID:
19895363
8.

Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia.

Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL.

Pharmacotherapy. 2010 May;30(5):453-62. doi: 10.1592/phco.30.5.453.

PMID:
20411997
9.

Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.

Réa-Neto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K, Ketter N, Prokocimer P, Friedland I.

Curr Med Res Opin. 2008 Jul;24(7):2113-26. doi: 10.1185/03007990802179255 . Epub 2008 Jun 11.

PMID:
18549664
10.

A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.

Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, Cirillo I, Kimko H, Redman R.

Crit Care. 2012 Nov 13;16(6):R218. doi: 10.1186/cc11862.

11.

Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia.

Eagye KJ, Nicolau DP, Kuti JL.

Semin Respir Crit Care Med. 2009 Feb;30(1):116-23. doi: 10.1055/s-0028-1119815. Epub 2009 Feb 6. Review.

PMID:
19199193
12.

Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials.

Jenkins SG, Fisher AC, Peterson JA, Nicholson SC, Kaniga K.

Curr Med Res Opin. 2009 Dec;25(12):3029-36. doi: 10.1185/03007990903396790.

PMID:
19849650
13.

Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia.

Zilberberg MD, Mody SH, Chen J, Shorr AF.

Surg Infect (Larchmt). 2010 Oct;11(5):409-17. doi: 10.1089/sur.2009.076.

PMID:
20666580
14.

Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.

Luyt CE, Aubry A, Lu Q, Micaelo M, Bréchot N, Brossier F, Brisson H, Rouby JJ, Trouillet JL, Combes A, Jarlier V, Chastre J.

Antimicrob Agents Chemother. 2014;58(3):1372-80. doi: 10.1128/AAC.02109-13. Epub 2013 Dec 16.

15.

The impact of ventilator-associated pneumonia on the Canadian health care system.

Muscedere JG, Martin CM, Heyland DK.

J Crit Care. 2008 Mar;23(1):5-10. doi: 10.1016/j.jcrc.2007.11.012. Review.

PMID:
18359415
17.

Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.

West M, Boulanger BR, Fogarty C, Tennenberg A, Wiesinger B, Oross M, Wu SC, Fowler C, Morgan N, Kahn JB.

Clin Ther. 2003 Feb;25(2):485-506.

PMID:
12749509
18.

A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study).

Mustafa M, Chan WM, Lee C, Harijanto E, Loo CM, Van Kinh N, Anh ND, Garcia J.

Int J Antimicrob Agents. 2014 Apr;43(4):353-60. doi: 10.1016/j.ijantimicag.2014.01.017. Epub 2014 Feb 15.

PMID:
24636429
19.

Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.

Matthews SJ, Lancaster JW.

Clin Ther. 2009 Jan;31(1):42-63. doi: 10.1016/j.clinthera.2009.01.013. Review.

PMID:
19243706
20.

A prospective study of ventilator-associated pneumonia in children.

Srinivasan R, Asselin J, Gildengorin G, Wiener-Kronish J, Flori HR.

Pediatrics. 2009 Apr;123(4):1108-15. doi: 10.1542/peds.2008-1211.

PMID:
19336369

Supplemental Content

Support Center